Skip to nav Skip to content
Matthew  Perez

Matthew Perez, MD

4.9 (121)

Specialty: Surgery

Program: Cutaneous Oncology

Language(s): English

  • Overview

    Cancer Focus:
    Melanoma, Skin Cancer (Nonmelanoma)

    Dr. Matthew Perez is as an Assistant Member in the Department of Cutaneous Oncology. Dr. Perez received his MD degree from the University of South Florida Morsani College of Medicine. He completed a General Surgery Residency at Emory University, Atlanta, Georgia, where he also served as Chief Resident. During his residency, he completed a Research Fellowship in the Department of Cutaneous Oncology at Moffitt Cancer Center. Dr. Perez most recently completed a Complex General Surgical Oncology Fellowship at Moffitt Cancer Center and the University of South Florida. Dr. Perez’s clinical and research interests focus on the surgical treatment of melanoma and other cutaneous malignancies and evaluating novel treatment strategies (intralesional, regional perfusion, and systemic therapies) for locally advanced or disseminated cutaneous malignancies.

  • Publications

    • Dugan MM, Perez MC, Karapetyan L, Zager JS. Management of acral lentiginous melanoma: current updates and future directions. Front Oncol. 2024 Feb.14:1323933. Pubmedid: 38390259. Pmcid: PMC10882087.
    • Huibers A, DePalo DK, Perez MC, Zager JS, Olofsson Bagge R. Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver. Clin Exp Metastas. 2023 Oct. Pubmedid: 37843790.
    • Perez MC, Messina JL, Karapetyan L, Neves RI, Sondak VK. Acral melanoma: clinical advances and hope for the future. Clin Adv Hematol Oncol. 2023 Aug.21(8):400-409. Pubmedid: 37530614.
    • Perez MC, Depalo DK, Zager JS. A safety review of recently approved and late-stage trial treatments for metastatic melanoma: systemic and regional therapies. Expert Opin Drug Saf. 2023 Aug.1-9. Pubmedid: 37551723.
    • DePalo DK, Perez MC, Huibers A, Bagge RO, Zager JS. Oncolytic intralesional therapy for metastatic melanoma. Clin Exp Metastas. 2023 Aug. Pubmedid: 37556092.
    • Castater C, Nguyen J, Perez M, Butler C, Meyer C, Todd SR, Sciarretta J, Smith R, Archer-Arroyo K, Grant A. Approaches to Repair of Penetrating Injuries of the Proximal, Mid, and Distal Esophagus. Am Surg. 2022 Mar.88(3):560-562. Pubmedid: 34693758.
    • Broman KK, Hughes TM, Bredbeck BC, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, O'shea K, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Hotz M, Farma JM, Deneve JL, Fleming MD, Perez M, Baecher K, Lowe M, Bagge RO, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley GM, Hui JYC, Been L, Kruijff S, Sinco B, Sarnaik AA, Sondak VK, Zager JS, Dossett LA. International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node Positive Melanoma at Major Referral Centers. Ann Surg. 2022 Jan. Pubmedid: 35129464.
    • Perez MC, Kim SC, Egunsola A, Reitz A, Archer-Arroyo K, Smith RN, Williams KN, Udobi K, Sola R, Dente CJ, Cristescu MM, Grant A, Nguyen J. Bleeding From a Hepatic Artery-Portal Vein Fistula After Repair of a Stab Wound to the Liver. Am Surg. 2021 Jun. Pubmedid: 34171964.
    • Broman KK, Hughes T, Dossett L, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma JM, Deneve JL, Fleming MD, Perez MC, Lowe MC, Olofsson Bagge R, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley G, Hui JYC, Been L, Kruijff S, Kim Y, Naqvi SMH, Sarnaik AA, Sondak VK, Zager JS. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2). Cancer. 2021 Jul.127(13):2251-2261. Pubmedid: 33826754. Pmcid: PMC8764513.
    • Farley CR, Perez MC, Soelling SJ, Delman KA, Harit A, Wuthrick EJ, Messina JL, Sondak VK, Zager JS, Lowe MC. Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?. Ann Surg Oncol. 2020 Jun.27(6):1978-1985. Pubmedid: 32103415.
    • Farley CR, Perez MC, Soelling SJ, Delman KA, Harit A, Wuthrick EJ, Messina JL, Sondak VK, Zager JS, Lowe MC. Correction to: Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?. Ann Surg Oncol. 2020 Dec.27(Suppl 3):983. Pubmedid: 32699930.
    • Perez MC, Sun J, Farley C, Han D, Sun AH, Narayan D, Lowe M, Delman KA, Messina JL, Gonzalez RJ, Sondak VK, Khushalani NI, Zager JS. Management of intussusception in patients with melanoma. J Surg Oncol. 2019 Jun.119(7):897-902. Pubmedid: 30734297.
    • Perez MC, Zager JS, Amatruda T, Conry R, Ariyan C, Desai A, Kirkwood JM, Treichel S, Cohan D, Raskin L. Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1). Melanoma Manag. 2019 Jul.6(2):MMT19. Pubmedid: 31406563. Pmcid: PMC6688558.
    • Davis EJ, Perez MC, Ayoubi N, Zhao S, Ye F, Wang DY, Sosman JA, Al-Rohil RN, Eroglu Z, Johnson DB. Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma. J Immunother. 2019 Jul.42(6):221-227. Pubmedid: 30882548. Pmcid: PMC6561788.
    • Perez MC, Oliver DE, Weitman ES, Boulware D, Messina JL, Torres-Roca J, Cruse CW, Gonzalez RJ, Sarnaik AA, Sondak VK, Wuthrick EJ, Harrison LB, Zager JS. Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?. Ann Surg Oncol. 2019 Feb.26(2):379-385. Pubmedid: 30311164. Pmcid: PMC7771265.
    • Weitman ES, Perez MC, Lee D, Kim Y, Fulp W, Sondak VK, Sarnaik AA, Gonzalez RJ, Cruse CW, Messina JL, Zager JS. Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins. Melanoma Manag. 2019 Apr.6(2):MMT17. Pubmedid: 31406562. Pmcid: PMC6688556.
    • Louie RJ, Perez MC, Jajja MR, Sun J, Collichio F, Delman KA, Lowe M, Sarnaik AA, Zager JS, Ollila DW. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience. J Am Coll Surg. 2019 Apr.228(4):644-649. Pubmedid: 30690076.
    • Perez MC, de Pinho FR, Holstein A, Oliver DE, Naqvi SMH, Kim Y, Messina JL, Burke E, Gonzalez RJ, Sarnaik AA, Cruse CW, Wuthrick EJ, Harrison LB, Sondak VK, Zager JS. Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough?. Ann Surg Oncol. 2018 Oct.25(11):3334-3340. Pubmedid: 30073600. Pmcid: PMC7771268.
    • Perez MC, Orcutt ST, Zager JS. Current standards of surgical management in primary melanoma. G Ital Dermatol Venereol. 2018 Feb.153(1):56-67. Pubmedid: 28895666.
    • Perez MC, Zager JS. ASO Author Reflections: Resection Margins in Merkel Cell Carcinoma: Is a 1 cm Margin Wide Enough?. Ann Surg Oncol. 2018 Dec.25(Suppl 3):901. Pubmedid: 30151562.
    • Perez MC, Miura JT, Naqvi SMH, Kim Y, Holstein A, Lee D, Sarnaik AA, Zager JS. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience. Ann Surg Oncol. 2018 Dec.25(13):3960-3965. Pubmedid: 30298318. Pmcid: PMC7771271.
    • Perez MC, Yu HM, Markowitz J. Severe thromboembolic phenomenon in the setting of pseudoprogression of melanoma brain metastases in response to combination immunotherapy. BMJ Case Rep. 2018 Aug.2018. Pubmedid: 30108120. Pmcid: PMC6101337.
    • Abbott AM, Doepker MP, Kim Y, Perez MC, Gandle C, Thomas KL, Choi J, Shridhar R, Zager JS. Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma. Am J Clin Oncol. 2018 Aug.41(8):747-753. Pubmedid: 28059929. Pmcid: PMC7771287.
    • Weitman ES, Perez M, Thompson JF, Andtbacka RHI, Dalton J, Martin ML, Miller T, Gwaltney C, Sarson D, Wachter E, Zager JS. Quality of life patient-reported outcomes for locally advanced cutaneous melanoma. Melanoma Res. 2018 Apr.28(2):134-142. Pubmedid: 29261570. Pmcid: PMC5844587.
    • Rossfeld K, Hade EM, Gangi A, Perez M, Kinsey EN, Grabska J, Ederle A, Zager J, Salama AK, Olencki TE, Beasley GM. Metastatic melanoma patients' sensitivity to ipilimumab cannot be predicted by tumor characteristics. Int J Surg Oncol (N Y). 2017 Oct.2(9):e43. Pubmedid: 29177235. Pmcid: PMC5673131.
    • O'Donoghue C, Perez MC, Mullinax JE, Hardman D, Sileno S, Naqvi SMH, Kim Y, Gonzalez RJ, Zager JS. Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions. Ann Surg Oncol. 2017 Dec.24(13):3842-3849. Pubmedid: 29019175. Pmcid: PMC7771340.
    • Mullinax JE, Kroon HM, Thompson JF, Nath N, Mosca PJ, Farma JM, Bhati R, Hardmann D, Sileno S, O'Donoghue C, Perez M, Naqvi SM, Chen YA, Gonzalez RJ, Zager JS. Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity Sarcoma. J Am Coll Surg. 2017 Apr.224(4):635-642. Pubmedid: 28214556. Pmcid: PMC7771304.
    • Forster MR, Rashid OM, Perez MC, Choi J, Chaudhry T, Zager JS. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. J Surg Oncol. 2014 Apr.109(5):434-439. Pubmedid: 24249545. Pmcid: PMC4503311.
    • Perez MC, Padhya TA, Messina JL, Jackson RS, Gonzalez RJ, Bui MM, Letson GD, Cruse CW, Lavey RS, Cheong D, Forster MR, Fulp WJ, Sondak VK, Zager JS. Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol. 2013 Oct.20(11):3391-3397. Pubmedid: 23835652. Pmcid: PMC4509495.
  • Patient Comments

    Overall Satisfaction

    4.9

    121 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey

     

    Comments

    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor